Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.52 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SAT1 | P21673 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21764815 | 0.81 | CYP3A4 (0.52) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL12555248 | 0.79 | CYP3A4 (0.50) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL25991329 | 0.79 | CYP3A4 (0.50) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL21764580 | 0.78 | CYP3A4 (0.48) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL21764572 | 0.78 | LPAR3 (0.52) | CYP3A4LPAR3LPAR2LPAR1S1PR2 | |
| SCHEMBL21764714 | 0.78 | CYP3A4 (0.48) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL21764956 | 0.78 | CYP3A4 (0.48) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL25121971 | 0.77 | LPAR3 (0.56) | LPAR3LPAR2LPAR1S1PR2S1PR4 | |
| SCHEMBL57561 | 0.77 | — | — | |
| SCHEMBL26432902 | 0.77 | CA2 (0.35) | LPAR3LPAR2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | AEQUOR, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | DDT, PFAS, DSTN | CYP3A4 2361/4885LPAR3 3397/4885LPAR2 3576/4885 |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | DDT, AS3MT, GPX4 | CYP3A4 1048/4885LPAR3 1324/4885LPAR2 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.